Getty ImagesNEW DELHI: Pharma major on Tuesday posted a 2.61 per cent year-on-year (YoY) decline in December quarter consolidated net profit at Rs 728.60 crore against Rs 748.15 crore. That said, the figure was higher than ET NOW poll of analysts estimate of Rs 710 crore.
The revenue from sales of products stood at Rs 5,442.86 crore in Q3 FY22, up 5.6 per cent YoY against Rs 5,154.17 crore in Q3FY21.
Total revenue from operations was at Rs 5,478.86 crore against ET NOW poll of Rs 5,420 crore.
The company board considered and approved the transfer of the India based US business undertaking to Cipla BioTec Limited, a wholly owned subsidiary of the Company for a consideration of Rs 1,400 crore and the consumer business Undertaking to Cipla Health Limited, wholly owned subsidiary of the company for a consideration of Rs 80 crore as a going concern on a slump sale basis through a Business Transfer Agreement (BTA).
On a standalone basis, the company said its profit rose 4.57 per cent to Rs 731 crore. The revenue from sales of products came in at Rs 3871 crore up 4.9 per cent against the year-ago quarter.
The revenue from sales of products stood at Rs 5,442.86 crore in Q3 FY22, up 5.6 per cent YoY against Rs 5,154.17 crore in Q3FY21.
Total revenue from operations was at Rs 5,478.86 crore against ET NOW poll of Rs 5,420 crore.
The company board considered and approved the transfer of the India based US business undertaking to Cipla BioTec Limited, a wholly owned subsidiary of the Company for a consideration of Rs 1,400 crore and the consumer business Undertaking to Cipla Health Limited, wholly owned subsidiary of the company for a consideration of Rs 80 crore as a going concern on a slump sale basis through a Business Transfer Agreement (BTA).
On a standalone basis, the company said its profit rose 4.57 per cent to Rs 731 crore. The revenue from sales of products came in at Rs 3871 crore up 4.9 per cent against the year-ago quarter.
Pick the best companies to invest
BECOME AN ETPRIME MEMBERRead More News on
(What's moving Sensex and Nifty Track latest market news, stock tips and expert advice on ETMarkets. Also, ETMarkets.com is now on Telegram. For fastest news alerts on financial markets, investment strategies and stocks alerts, subscribe to our Telegram feeds.)
...moreDownload The Economic Times News App to get Daily Market Updates & Live Business News.
Pick the best stocks for yourself
Powered by